



## PRESS RELEASE

*For immediate distribution*

SOURCE: DIAGNOS inc.

VENTURE TSX TICKER: ADK

### **Miraculins will use DIAGNOS' Artificial Intelligence for biomarkers discovery in prostate cancer test**

Brossard, Quebec, Canada – December 4, 2007 - DIAGNOS inc. ("DIAGNOS" or the "Corporation") (VENTURE TSX: ADK), a leader in the use of artificial intelligence ("AI") and advanced knowledge extraction techniques, is pleased to announce today that Miraculins will be using DIAGNOS technology towards the development of its cancer diagnostic discovery programs.

"I am confident and excited about the application of our Corporation's technology to the field of bio-diagnostics", said André Larente, President of DIAGNOS. "Our technology has been designed to accommodate to the complexity of the data that Miraculins is working with and I strongly believe that it will be of great value to the organization. The team of specialists at DIAGNOS has always wanted to participate in the field of cancer research because we believe that our technology can help identify, in the early stages, some of the key elements the industry needs to track. Using advanced data mining and Artificial Intelligence to analyze existing data from patients, we can learn to identify the key invariants required for detecting this disease with an acceptable sensibility and specificity."

"Biomarkers discovery research is a complicated process, especially when a large number of markers are found to be potential indicators of a disease," said Christopher J. Moreau, President and CEO of Miraculins. "Quite often there is a relationship not only with the suppression or over expression of a marker but how multiple markers relate and interact with each other in forming a panel test. Being able to utilize the most sophisticated algorithms and data mining techniques will provide us with a significant capability to not only discover meaningful biomarkers but to better understand how we can use the data generated to build more efficient models to better predict disease".

Highlights of the business contract:

- Miraculins will pay DIAGNOS a consulting fee up to a maximum of \$30,000 to review data and develop algorithms for its biomarkers discovery program, 50% of which will be paid in cash and 50% will be paid in shares of Miraculins issued once the work is completed;
- should DIAGNOS develop an algorithm for a diagnostic test that is used by Miraculins, DIAGNOS will receive a royalty of 5% of the actual gross commercial sales received by Miraculins per test, and in addition, DIAGNOS will also be granted 50,000 options, subject to regulatory approval. The exercise price of the options will be at the closing market price of Miraculins' shares on the date of grant.

#### About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's BEST™ Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarkers discovery.

#### About DIAGNOS

DIAGNOS inc. has developed data mining software and provides data mining services. The Corporation designed and developed MCubiX, a data mining software suite capable of extracting knowledge from historical data - in the form of images, text or traditional databases - and making predictions that improve business processes and decision making ability. For further information, please visit our website at [www.diagnos.ca](http://www.diagnos.ca). The Corporation's objective is to develop a royalty stream by significantly enhancing and participating in the creation of new applications for medical, financial, entertainment, mining and oil & gas markets.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

André Larente, President  
Telephone: (450) 678-8882, ext. 24  
[alarente@diagnos.ca](mailto:alarente@diagnos.ca)

Housseem Ben Tahar, Manager – Development and Business Intelligence  
Telephone: (450) 678-8882, ext. 31  
[housseem@diagnos.ca](mailto:housseem@diagnos.ca)